Insulet Corporation (PODD)
NASDAQ: PODD · IEX Real-Time Price · USD
197.19
+1.03 (0.53%)
At close: Jul 2, 2024, 4:00 PM
195.50
-1.69 (-0.86%)
After-hours: Jul 2, 2024, 7:06 PM EDT
Insulet Revenue
Insulet had revenue of $1.78B in the twelve months ending March 31, 2024, with 30.17% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $441.70M with 23.35% year-over-year growth. In the year 2023, Insulet had annual revenue of $1.70B with 30.02% growth.
Revenue (ttm)
$1.78B
Revenue Growth
+30.17%
P/S Ratio
7.76
Revenue / Employee
$593,567
Employees
3,000
Market Cap
13.81B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
Dec 31, 2017 | 463.80M | 96.81M | 26.38% |
Dec 31, 2016 | 366.99M | 103.10M | 39.07% |
Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
Dec 31, 2005 | 50.00K | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.91B |
Quest Diagnostics | 9.29B |
Incyte | 3.77B |
Revvity | 2.73B |
United Therapeutics | 2.50B |
BioMarin Pharmaceutical | 2.47B |
Neurocrine Biosciences | 1.98B |
Medpace Holdings | 1.96B |
PODD News
- 11 days ago - Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes - Business Wire
- 12 days ago - Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands - Business Wire
- 12 days ago - Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates - Business Wire
- 5 weeks ago - Insulet to Present at the Jefferies Global Healthcare Conference - Business Wire
- 7 weeks ago - Insulet misses first-quarter profit estimates as marketing costs weigh - Reuters
- 7 weeks ago - Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year - Business Wire
- 2 months ago - Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth - Business Wire
- 3 months ago - Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 - Business Wire